<DOC>
	<DOCNO>NCT01614405</DOCNO>
	<brief_summary>Patients primary biliary cirrhosis ( PBC ) develop progressive liver disease often require liver transplantation . The cause disease unknown . It think occur result infection subject susceptible disease others . The investigator find evidence retrovirus infection patient primary biliary cirrhosis . The investigator find patient PBC evidence viral infection . Since investigator conduct clinical study use anti-viral therapy . The investigator find PBC patient treat combination anti-retrovirus therapy experience significant reversal disease process . However , change substantial investigator look well antiviral regimen . Now investigators find mouse model similar virus infection develop similar biliary disease . Importantly , investigator find antiviral therapy block development disease mouse . The investigator use model find safer effective antiviral treatment patient PBC . The investigator find combination highly active antiretroviral therapy Truvada Kaletra stop disease mouse plan use combination see work patient PBC .</brief_summary>
	<brief_title>Highly Active Antiretroviral Therapy Patients With Primary Biliary Cirrhosis</brief_title>
	<detailed_description>6 month therapy blind Kaletra Truvada vs. 6 month therapy blind placebo follow 6 month open label therapy Kaletra Truvada 18 month extension study open label Kaletra Truvada patient complete 6 month therapy Kaletra Truvada biochemical endpoint</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Liver Cirrhosis , Biliary</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>1 . Patients 18 year old either sex recruit study . 2 . Elevated ALP 6 month UDCA therapy â‰¥ 2 x upper limit normal abnormal bilirubin . 3 . Positive serum AMA Liver biopsy histology compatible PBC . 4 . Maintained UDCA dose 1315 mg/kg 6 month . 5 . Patients must read sign informed consent form 1 . Subjects baseline AST ALT &gt; 5 x ULN . 2 . Patients alter dose medication use treat PBC ( UDCA ) use colchicine , corticosteroid , azathioprine , chlorambucil , methotrexate , Dpenicillamine within last 6 month . 3 . Advanced liver disease esophageal varix , INR &gt; 1.2 ( upper limit normal ) , Albumin &lt; 35 g/L ( low limit normal ) , platelets &lt; 120,000/mm3 , Childs Pugh class B C cirrhosis , presence varix previous variceal hemorrhage , spontaneous encephalopathy , ascites need liver transplantation . 4 . Patients secondary diagnosis HIV , viral hepatitis , drug induce liver injury , extrahepatic biliary obstruction , primary sclerosing cholangitis , metabolic liver diseases alcoholic liver disease Regular use 30 g alcohol per day last year . Clinically apparent pancreatitis predict survival le 3 year malignant potentially life threaten disease . 5 . An ultrasound showing hepatic mass consistent hepatocellular carcinoma within last year patient cirrhosis . 6 . Previous allergic reaction study medication . 7 . Creatinine clearance less &lt; 70 mL/min use Cockcroft Gault equation : Creatinine clearance ( mL/min ) = ( 140 age ) x body wt ( Kg ) x 0.85 ( female ) /serum creatinine mol/l 8 . Pregnancy breastfeed child . Young sexually active patient use contraception 9 . Young sexually active patient use contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>PBC</keyword>
</DOC>